Trials / Active Not Recruiting
Active Not RecruitingNCT06441214
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 212 (actual)
- Sponsor
- Fondazione Italiana Linfomi - ETS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional, observational, retrospective and prospective multicenter Italian study, to describe treatment management and outcomes of Waldenström's Macroglobulinemia (WM) patients treated according to the Italian Compassionate Use Program (CUP) and receiving zanubrutinib following its commercial approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Patients will be treated with Zanubrutinib as per routine clinical practice. |
Timeline
- Start date
- 2024-12-13
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-06-04
- Last updated
- 2026-01-05
Locations
28 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06441214. Inclusion in this directory is not an endorsement.